5AM Venture Management, LLC

In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), 5AM Venture Management, LLC reported 28 stock positions worth $484.0 million. Its top holding was Entrada Therapeutics (TRDA) at 14.6% of the portfolio, followed by Enliven Therapeutics (ELVN, 9.2%) and Skye Bioscience (SKYE, 8.0%). Compared with Q2 2024, it opened 1 new position, sold out of 1, added to 3 and reduced 4. The biggest buy was a new position in Artiva Biotherapeutics (ARTV) and the biggest sale Skye Bioscience (SKYE, shares −3%).

Most Recent 13F
Q2 2026
Location
SAN FRANCISCO, CA
CIK
0001799883
Portfolio Value
$484.0M (Q3 2024)
SEC Filing
0001104659-24-118921 ↗ filed Nov 14, 2024

Holdings Value

0$100.0M$200.0M$300.0M$400.0M$500.0M Q1 2024: $446.6M Q1 2024 Q2 2024: $447.1M Q2 2024 Q3 2024: $484.0M $484.0M Q3 2024 Q4 2024: $419.1M Q4 2024 Q1 2025: $264.4M Q1 2025 Q2 2025: $260.1M Q2 2025 Q3 2025: $273.0M Q3 2025 Q4 2025: $318.1M Q4 2025 Q1 2026: $360.2M Q1 2026 Q2 2026: $287.9M Q2 2026

Holdings 28 stocks · $484.0M
TRDA Entrada Therapeutics Inc. 14.55% 4,408,379 $70.4M No change
ELVN Enliven Therapeutics Inc. 9.25% 1,752,174 $44.8M Reduce -32.9%
SKYE Skye Bioscience Inc. 8.01% 9,913,168 $38.8M Reduce -2.6%
ARTV Artiva Biotherapeutics Inc. 7.51% 2,353,304 $36.4M New
DNTH Dianthus Therapeutics Inc. 6.97% 1,231,619 $33.7M Reduce -0.1%
BHVN Biohaven Ltd. 4.95% 478,972 $23.9M Add +1.9%
TYRA Tyra Biosciences Inc. 4.56% 939,298 $22.1M No change
CNTA Centessa Pharmaceuticals Ltd. 4.25% 1,285,000 $20.5M Add +3.2%
TECX Tectonic Therapeutic Inc. 4.05% 646,524 $19.6M No change
PRAX Praxis Precision Medicines I 4.04% 340,000 $19.6M No change
CLDX Celldex Therapeutics Inc. 3.49% 497,270 $16.9M No change
VRDN Viridian Therapeutics Inc. 3.46% 736,595 $16.8M No change
VKTX Viking Therapeutics Inc. 3.11% 237,560 $15.0M No change
PHVS Pharvaris NV 3.05% 797,600 $14.8M No change
ERAS Erasca Inc. 3.05% 5,405,404 $14.8M No change
MLTX Moonlake Immunotherapeutics 2.94% 282,313 $14.2M No change
ANAB Anaptysbio Inc. 2.48% 357,733 $12.0M No change
SLN Silence Therapeutics PLC-ADR 1.79% 476,200 $8.7M No change
EYPT Eyepoint Inc. 1.73% 1,050,000 $8.4M Add +2000.0%
COGT Cogent Biosciences Inc. 1.25% 561,854 $6.1M Reduce -28.9%
SCPH Scpharmaceuticals Inc. 1.13% 1,200,647 $5.5M No change
VOR Vor Biopharma Inc. 0.92% 6,361,723 $4.5M No change
RLYB Rallybio Corp. 0.88% 3,630,724 $4.2M No change
GHRS GH Research PLC 0.79% 572,665 $3.8M No change
ADVM Adverum Biotechnologies Inc. 0.79% 541,666 $3.8M No change
MERSANA THERAPEUTICS INC 0.51% 1,305,000 $2.5M No change
ZNTL Zentalis Pharmaceuticals Inc. 0.37% 490,000 $1.8M No change
CDTX Cidara Therapeutics Inc. 0.13% 56,725 $610K No change

Portfolio Sells Q2 2024 → Q3 2024
SKYE Skye Bioscience Inc. Reduce -2.6% 8.01% −10.23
ELVN Enliven Therapeutics Inc. Reduce -32.9% 9.25% −4.40
QTTB Q32 Bio Inc. Sold out 0.00% −1.01
COGT Cogent Biosciences Inc. Reduce -28.9% 1.25% −0.24
DNTH Dianthus Therapeutics Inc. Reduce -0.1% 6.97% −0.17

Portfolio Buys Q2 2024 → Q3 2024
ARTV Artiva Biotherapeutics Inc. New 7.51% +7.51
CNTA Centessa Pharmaceuticals Ltd. Add +3.2% 4.25% +1.73
EYPT Eyepoint Inc. Add +2000.0% 1.73% +1.64
BHVN Biohaven Ltd. Add +1.9% 4.95% +1.30

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 16$287.9MMPLT, TYRA, TRDA, PHVS, CAMP
Q1 2026 20$360.2MERAS, TRDA, TYRA, CAMP, CNTA
Q4 2025 21$318.1MTRDA, CAMP, TYRA, VRDN, PHVS
Q3 2025 25$273.0MSKYE, TRDA, PHVS, CAMP, CNTA
Q2 2025 29$260.1MSKYE, TRDA, DNTH, ELVN, PHVS
Q1 2025 31$264.4MTRDA, ELVN, DNTH, SKYE, PHVS
Q4 2024 31$419.1MTRDA, ELVN, SKYE, TECX, ARTV
Q3 2024 28$484.0MTRDA, ELVN, SKYE, ARTV, DNTH
Q2 2024 28$447.1MSKYE, TRDA, ELVN, DNTH, CLDX
Q1 2024 26$446.6MELVN, TRDA, DNTH, MRUS, CLDX